Cumberland Pharmaceuticals Inc. CPIX
7.61
(0.40)
(4.99%)
as of 25 Sep
- Market cap
- $120.0M
- P/E
- 0.0×
Follow CPIX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (48.76%) | (29.74%) | (12.05%) | (13.24%) |
+8 more TTM periods Free account |
|
| (16.70%) | (10.48%) | (3.72%) | (4.67%) | ||
ROIC |
(34.23%) | (29.02%) | (9.51%) | (22.23%) | |
Return on Tangible Assets |
837.82% | 505.19% | (488.90%) | (56.19%) | |
Average Days of Receivables |
117.39 | 124.12 | 138.92 | 123.52 | |
Free Cash Flow per Share |
0.04 | 0.09 | 0.32 | 0.45 | |
Free Cash Flow |
0.58 | 1.34 | 4.75 | 6.67 | |
Capital Expenditures |
(0.17) | (0.09) | (0.18) | (0.17) | |
Piotroski F-Score |
4.00 | 4.00 | 6.00 | 6.00 | |
| Other line items | |||||
Cash ROIC |
3.56% | 3.78% | 11.96% | 14.78% | |
Accounts Receivable Turnover |
3.52 | 3.39 | 3.11 | 2.84 | |
Accounts Payable Turnover |
0.00 | 0.60 | 0.53 | 0.49 | |
Inventory Turnover |
0.00 | 1.92 | 4.31 | 1.72 | |
Average Days of Payables |
0.00 | 657.03 | 780.91 | 788.59 | |
Days of Inventory on Hand |
0.00 | 216.68 | 1.26 | 167.31 | |
Tax Rate |
0.01 | 0.01 | 0.01 | (0.01) | |
Research and Development Expense of Revenue |
13.58% | 13.66% | 12.50% | 15.18% | |
Selling, General and Administrative Expense of Revenue |
76.36% | 76.23% | 69.73% | 77.56% | |
Share Based Compensation of Revenue |
1.05% | 1.05% | 0.92% | 1.01% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.07) | (0.19) | (1.74) | (2.05) | |
Depreciation/Fixed assets |
16.64 | 18.49 | 15.66 | 15.68 | |
Capex/Depreciation |
(0.04) | (0.02) | (0.04) | (0.04) | |
Revenue per Share |
2.79 | 2.80 | 3.00 | 2.06 | |
Operating CF per Share |
0.05 | 0.10 | 0.33 | 0.46 | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.01 | |
Net Profit Margin |
(26.17%) | (17.60%) | (6.37%) | (10.80%) |
Columns are period end dates